ASCO 2014: Autour de la thrombose…

Voici différents posters autour de la thrombose qui seront présentés lors de l’ASCO 2014, ou bien présentés en ligne sur le site de l’ASCO.
En cliquant sur le lien, vous serez redirigé directement sur l’abstract.

1. Thrombosis in a population of phase I trial patients. | 2014 ASCO Annual Meeting Abstracts
Skip to main content Advertisement Welcome Thrombosis in a population of phase I trial patients.Sub-category: Outcomes and Quality of Care Category: Health Services Research Meeting
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_133969.html


2. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: Results of the CAVECCAS study. | 2014 ASCO Annual Meeting Abstracts
Skip to main content Advertisement Welcome Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: Results of the CAVECCAS study.Sub-category: Symptom
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_133217.html


3. Incidence of incidental and symptomatic venous thromboembolism (VTE) and Khorana’s score in ambulatory pancreatic cancer patients receiving chemotherapy. | 2014 ASCO Annual Meeting Abstracts
, Maitane Mugica, Cynthia S. González Rivas, Paula Jiménez-Fonseca, Cancer and Thrombosis Working Group, Spanish Society of Medical Oncology (SEOM); Hospital General
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_132357.html


4. The impact of prothrombotic mutations, PSGL-1 VNTR polymorphism, tissue factor, and soluble P-selectin on venous thromboembolism in cancer patients with adenocarcinoma. | 2014 ASCO Annual Meeting Abstracts
and the patients were treated accordingly. We defined VTE by sites as deep venous thrombosis (DVT), pulmonary embolism (PE), other vascular territories (
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_134758.html


5. Experience of a small cancer center from Brazil with implantable port systems in the brachial veins. | 2014 ASCO Annual Meeting Abstracts
date of implantation and incidence of late adverse events such as infection, obstruction and thrombosis. Results: A total of 102 port systems were implanted in the brachial
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_133850.html


6. Antiangiogenic-specific adverse events (AEs) in patients with non-small cell lung cancer (NSCLC) treated with nintedanib (N) and docetaxel (D). | 2014 ASCO Annual Meeting Abstracts
use is limited in part by their characteristic side effects (eg, bleeding, thrombosis, perforation, serious skin reactions, hypertension). N is an oral
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_134123.html


7. Venous thromboembolism (VTE) and glioblastoma. | 2014 ASCO Annual Meeting Abstracts
139 documented events. 56 pts (42%) were diagnosed with deep vein thrombosis (DVT), 27 pts (20%) with pulmonary emboli (
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_135329.html


8. Docetaxel (DOC) with concurrent radiation (CRT) and bevacizumab (BEV) or erlotinib (ERL) for locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). | 2014 ASCO Annual Meeting Abstracts
/ERL related events limited to 2 G4 bleeding episodes and 1 G3 episode of thrombosis (BEV); 4 G4 skin rash episodes and 1 G5 event (
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_132093.html


9. Results of a prospective, randomized, open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial | 2014 ASCO Annual Meeting Abstracts
disease-related symptom burden (eg, pruritus), and risk of vascular events (thrombosis and/or hemorrhage). Maintaining hematocrit (HCT) control is a
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_133669.html


10. DEB40µm-TACE: Early single-center results in 23 patients. | 2014 ASCO Annual Meeting Abstracts
. Complications during follow-up occured in 3 out of 20 patients (1 portal vein thrombosis (at 6 months), 1 intrahepatic abscess under subsequent sorafenib-therapy (at
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_133981.html


11. Role of paclitaxel and platinum-based chemotherapy in locally advanced and metastatic penile squamous cell carcinoma. | 2014 ASCO Annual Meeting Abstracts
. No patient had grade 2 neutropenia. One patient died after developing deep venous thrombosis and inguinal lymph node bleeding. Subsequent treatment was provided to 12 pts (
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_134993.html


12. The differential clinicopathologic features and survival outcome between hepatitis C–related HCC patients in the United States versus Egypt. | 2014 ASCO Annual Meeting Abstracts
appears in the form of higher vascular invasion (P .004), Portal vein thrombosis (PVT) (P .0008), lymph node metastasis (P .0004
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_134529.html


13. Incidence of cardiovascular events in the real-world population of cancer patients treated with targeted therapies. | 2014 ASCO Annual Meeting Abstracts
stroke, hemorrhagic stroke, cardiac arrest, hypertension (HTN), deep venous thrombosis (DVT), pulmonary embolus, and CV death. Statistical analysis:
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_134125.html


14. Venous thromboembolism in patients with glioblastoma multiforme. | 2014 ASCO Annual Meeting Abstracts
: We studied consecutive Cleveland Clinic patients with GBM presenting with objectively diagnosed deep vein thrombosis (DVT) or pulmonary embolism (PE) from 2008 to 2013 with
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_131553.html


15. Practice of venous thromboembolism (VTE) prophylaxis in hospitalized cancer patients at a comprehensive cancer center. | 2014 ASCO Annual Meeting Abstracts
plan to monitor and analyze anticoagulation-related outcomes as well as mortality and morbidity related to thrombosis and bleeding in this cohort of patients. VTE risk assessment and prophylaxis (
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_133922.html


16. Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type. | 2014 ASCO Annual Meeting Abstracts
%), infection (8 %), hyponatremia (8 %), thrombosis (4 %), urticaria (4 %), anorexia (4
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_130960.html


17. Comparison of a new prognostic system and four current staging systems in predicting the survival rate of patients with advanced hepatocellular carcinoma. | 2014 ASCO Annual Meeting Abstracts
50% of the liver Bun 8.9 >8.9 AFP 400 >400 Portal vein thrombosis No Yes Other Abstracts in this Sub-Category: 1. ABC-03: A randomized
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_128764.html


18. Safety, tolerability, and pharmacokinetics (PK) of rilotumumab (R) combined with cisplatin (C) and capecitabine (X) in Japanese patients (pts) with MET-positive metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. | 2014 ASCO Annual Meeting Abstracts
grade 4 TRAE (neutropenia). One pt discontinued R due to nonserious arterial thrombosis. There were no life-threatening or fatal R-related AEs. The mean end-of-infusion concentrations
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_128778.html


19. Alliance A091103: A multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib (AMG386) for the treatment of angiosarcoma (AS). | 2014 ASCO Annual Meeting Abstracts
% CI 17-48). Common grade 3-4 adverse events include (pts): thrombosis (2 ), syncope (1 ), anemia (1).
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_128367.html


20. ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS). | 2014 ASCO Annual Meeting Abstracts
Gr1/1 Gr5) and WP-B (2 Gr1/1 Gr2), thrombosis in both arms: WP (1 Gr1) and WP-B (1 Gr2
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_126805.html


21. Use of lipid-lowering drugs in patients with cancer. | 2014 ASCO Annual Meeting Abstracts
event (myocardial infarction in 56 patients, cardiovascular accident in 24 patients and arterial thrombosis in 11 patients). In 241 Pt lowering-lipid drugs were indicated as primary
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_126479.html


22. Incidence of venous thromboembolism (VTE) in ambulatory day oncology patients. | 2014 ASCO Annual Meeting Abstracts
important causes of morbidity and mortality in cancer patients. VTE commonly includes deep vein thrombosis (DVT) and pulmonary embolism (PE). The risk of VTE
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_126754.html


23. A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC). | 2014 ASCO Annual Meeting Abstracts
include fatigue, dyslipidemia, and proteinuria. The most serious toxicity included deep vein thrombosis (1 ), esophageal fistula (1 ), bowel perforation (1
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_129581.html


24. Сapecitabine with cisplatin or with oxaliplatin in first-line chemotherapy in patients with metastatic gastric carcinoma (mGC): Single-center experience. | 2014 ASCO Annual Meeting Abstracts
groups were neutropenia 14,9% and 16,1 %, deep venous thrombosis – 1% and 0%, diarrhea – 4.1% and 7,
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_129603.html


25. Phase II trial of bevacizumab, cisplatin, and pemetrexed in Japanese patients with advanced nonsquamous non-small cell lung cancer. | 2014 ASCO Annual Meeting Abstracts
, grade 3 hypertensions in 8 (17.8%) and grade 2 deep vein thrombosis in 1 patient (2.2%). Conclusions: The Bevacizumab/PEM
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_130691.html


26. Safety of EBUS TBNA in patients with mediastinal and hilar adenopathy taking clopidogrel. | 2014 ASCO Annual Meeting Abstracts
performed after 5-7 days. If clopidogrel couldn’t be held due to high risk of thrombosis (based on the prescribing team’s recommendation), the patient was included.
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_130948.html


27. Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. | 2014 ASCO Annual Meeting Abstracts
/9 %) were similar across all arms. Grade> 3 hypertension/thrombosis/proteinuria/hemorrhage was reported by 8/3 /< 1 /
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_130506.html


28. Predictors and outcomes of venous thromboembolism (VTE) in hospitalized lung cancer patients: A nationwide inpatient sample (NIS) database analysis. | 2014 ASCO Annual Meeting Abstracts
Patients with lung cancer are at high risk of developing VTE, including deep venous thrombosis and pulmonary embolism. We sought to characterize the clinical factors associated with the
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_130499.html


29. SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism. | 2014 ASCO Annual Meeting Abstracts
) comparing the duration of therapy (6 vs 12 months) in residual vein thrombosis (RVT) positive patients. 70% of patients are estimated to be
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_129613.html


30. Outpatient management of cancer-related pulmonary embolism: Analysis of 562 consecutive patients from the EPIPHANY study. | 2014 ASCO Annual Meeting Abstracts
in symptomatic pulmonary embolism (PE). Nowadays, the increasing diagnosis of incidental thrombosis in scheduled CT scans implies a change in PE presentation. Clinical guidelines suggest
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_130386.html


31. A cross-section study evaluating patients’ satisfaction with totally implanted access ports (PAC) assessing the PAC-related complication rate at two tertiary care centres in Austria. | 2014 ASCO Annual Meeting Abstracts
; 1.7%), PAC malfunction (ten cases; 4.45%) and thrombosis (four cases; 1.7%). In total, 28 PAC systems
Terms matched: 1  –  URL: http://abstracts.asco.org/144/AbstView_144_125523.html